Literature DB >> 15295006

Targeted CTLA-4 engagement induces CD4+CD25+CTLA-4high T regulatory cells with target (allo)antigen specificity.

Chenthamarakshan Vasu1, Bellur S Prabhakar, Mark J Holterman.   

Abstract

CTLA-4 (CD152) is actively involved in down-regulating T cell activation and maintaining lymphocyte homeostasis. Our earlier studies showed that targeted engagement of CTLA-4 can down-modulate T cell response and suppress allo- and autoimmune responses. In this study, we report that targeted CTLA-4 engagement can induce immune tolerance to a specific target through selective induction of an Ag-specific CD4(+)CD25(+)CTLA-4(high) regulatory T cell (Treg cell) population. Allogeneic cells coated with anti-CTLA-4 Ab induced immune hyporesponsiveness through suppression of proinflammatory cytokines IFN-gamma and IL-2, and up-regulation of the regulatory cytokines IL-10, TGF-beta1, and IL-4, presumably through the engagement of CTLA-4 on activated T cells. Although rechallenge with alloantigen failed to break the unresponsiveness, a transient recovery from tolerance was observed in the presence of high concentrations of exogenous IL-2, saturating concentrations of neutralizing anti-TGF-beta1 and anti-IL-10 Abs, and blocking anti-CTLA-4 Ab, and upon depletion of CD4(+)CD25(+) Treg cells. The CD4(+)CD25(+)CTLA-4(high) Treg cells from tolerant mice suppressed the effector function of CD25(-) T cells from Ag-primed mice. Adoptive transfer of these Treg cells into Ag-primed mice resulted in a significantly reduced alloantigen-specific response. Further characterization demonstrated that the Treg cells with memory phenotype (CD62L(-)) were more potent in suppressing the alloantigen-specific T cell response. These results strongly support that the targeted engagement of CTLA-4 has therapeutic potential for the prevention of transplant rejection.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15295006     DOI: 10.4049/jimmunol.173.4.2866

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  21 in total

1.  Effect of CD4(+)CD25(+) regulatory T cells in the development of anterior chamber-associated immune deviation.

Authors:  Shu-Xing Ji; Xiao-Lei Yin; Pei-Zeng Yang
Journal:  Int J Ophthalmol       Date:  2011-02-18       Impact factor: 1.779

2.  Preferential costimulation by CD80 results in IL-10-dependent TGF-beta1(+) -adaptive regulatory T cell generation.

Authors:  Nicolas Perez; Subha Karumuthil-Melethil; Ruobing Li; Bellur S Prabhakar; Mark J Holterman; Chenthamarakshan Vasu
Journal:  J Immunol       Date:  2008-05-15       Impact factor: 5.422

3.  Aberrant expression of costimulatory molecules in splenocytes of the mevalonate kinase-deficient mouse model of human hyper-IgD syndrome (HIDS).

Authors:  Elizabeth J Hager; Jon D Piganelli; Hubert M Tse; K Michael Gibson
Journal:  J Inherit Metab Dis       Date:  2011-05-24       Impact factor: 4.982

4.  Dendritic cell-directed CTLA-4 engagement during pancreatic beta cell antigen presentation delays type 1 diabetes.

Authors:  Subha Karumuthil-Melethil; Nicolas Perez; Ruobing Li; Bellur S Prabhakar; Mark J Holterman; Chenthamarakshan Vasu
Journal:  J Immunol       Date:  2010-05-14       Impact factor: 5.422

5.  CTLA-4 blockade decreases TGF-beta, IDO, and viral RNA expression in tissues of SIVmac251-infected macaques.

Authors:  Anna Hryniewicz; Adriano Boasso; Yvette Edghill-Smith; Monica Vaccari; Dietmar Fuchs; David Venzon; Janos Nacsa; Michael R Betts; Wen-Po Tsai; Jean-Michel Heraud; Brigitte Beer; Diann Blanset; Claire Chougnet; Israel Lowy; Gene M Shearer; Genoveffa Franchini
Journal:  Blood       Date:  2006-08-08       Impact factor: 22.113

6.  Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4.

Authors:  Peter Attia; Giao Q Phan; Ajay V Maker; Michael R Robinson; Martha M Quezado; James C Yang; Richard M Sherry; Suzanne L Topalian; Udai S Kammula; Richard E Royal; Nicholas P Restifo; Leah R Haworth; Catherine Levy; Sharon A Mavroukakis; Geoff Nichol; Michael J Yellin; Steven A Rosenberg
Journal:  J Clin Oncol       Date:  2005-08-08       Impact factor: 44.544

7.  A novel pancreatic β-cell targeting bispecific-antibody (BsAb) can prevent the development of type 1 diabetes in NOD mice.

Authors:  Palash Bhattacharya; Jilao Fan; Christine Haddad; Abdul Essani; Anupama Gopisetty; Hatem A Elshabrawy; Chenthamarakshan Vasu; Bellur S Prabhakar
Journal:  Clin Immunol       Date:  2014-05-02       Impact factor: 3.969

8.  Heme oxygenase-1 attenuates ovalbumin-induced airway inflammation by up-regulation of foxp3 T-regulatory cells, interleukin-10, and membrane-bound transforming growth factor- 1.

Authors:  Zhen-Wei Xia; Li-Qing Xu; Wen-Wei Zhong; Jing-Jing Wei; Ning-Li Li; Jie Shao; Yun-Zhu Li; Shan-Chang Yu; Zi-Li Zhang
Journal:  Am J Pathol       Date:  2007-11-08       Impact factor: 4.307

Review 9.  Function of tumor necrosis factor receptor family members on regulatory T-cells.

Authors:  Robert H Arch
Journal:  Immunol Res       Date:  2005       Impact factor: 2.829

10.  Prognostic factors related to clinical response in patients with metastatic melanoma treated by CTL-associated antigen-4 blockade.

Authors:  Stephanie G Downey; Jacob A Klapper; Franz O Smith; James C Yang; Richard M Sherry; Richard E Royal; Udai S Kammula; Marybeth S Hughes; Tamika E Allen; Catherine L Levy; Michael Yellin; Geoffrey Nichol; Donald E White; Seth M Steinberg; Steven A Rosenberg
Journal:  Clin Cancer Res       Date:  2007-11-02       Impact factor: 12.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.